CSF2 and lung carcinoma: One possible explanation for this difference is the lower utilization of prophylactic colony-stimulating factors (CSF) or antimicrobial (AMB) agents in lung cancer patients (49.1%) compared to ovarian cancer patients (57.4%) in the retrospective study [51], as prophylaxis has been shown to significantly reduce FN risk [54].